Cargando…

Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration

Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss in the elderly. The gold standard of nAMD treatment is intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors. Genetic factors may influence the response to anti-VEGF therapy and result i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozhevnikova, Oyuna S., Fursova, Anzhella Zh., Derbeneva, Anna S., Nikulich, Ida F., Tarasov, Mikhail S., Devyatkin, Vasiliy A., Rumyantseva, Yulia V., Telegina, Darya V., Kolosova, Nataliya G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312436/
https://www.ncbi.nlm.nih.gov/pubmed/35884963
http://dx.doi.org/10.3390/biomedicines10071658
_version_ 1784753846267936768
author Kozhevnikova, Oyuna S.
Fursova, Anzhella Zh.
Derbeneva, Anna S.
Nikulich, Ida F.
Tarasov, Mikhail S.
Devyatkin, Vasiliy A.
Rumyantseva, Yulia V.
Telegina, Darya V.
Kolosova, Nataliya G.
author_facet Kozhevnikova, Oyuna S.
Fursova, Anzhella Zh.
Derbeneva, Anna S.
Nikulich, Ida F.
Tarasov, Mikhail S.
Devyatkin, Vasiliy A.
Rumyantseva, Yulia V.
Telegina, Darya V.
Kolosova, Nataliya G.
author_sort Kozhevnikova, Oyuna S.
collection PubMed
description Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss in the elderly. The gold standard of nAMD treatment is intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors. Genetic factors may influence the response to anti-VEGF therapy and result in a high degree of response variability. The aim of the study was to evaluate the association of the polymorphisms in genes related to the complement system (rs2285714-CFI, rs10490924-ARMS2, rs2230199-C3, rs800292-CFH, and rs6677604-CFH) with nAMD its clinical features and optical coherent tomography (OCT) biomarkers of treatment response to anti-VEGF therapy. Genotyping by allele-specific PCR was performed in 193 AMD patients and 147 age-matched controls. A prospective study of the dynamics of changes in OCT biomarkers during aflibercept treatment included 110 treatment-naive patients. Allele T rs10490924 was associated with the increased risk of nAMD. For both rs800292 and rs6677604, carriage of the A allele was protective and decreased the nAMD risk. Associations of rs2230199 with central retinal thickness (CRT) and intraretinal cysts were revealed. The height of pigment epithelium detachment and the height of neuroretinal detachment were significantly higher in carriers of the minor allele of rs2285714, both at baseline and during treatment. The reduction of CRT was associated with higher CRT at baseline and the presence of the T allele of rs2285714. By the end of one-year follow-up the patients homozygous for the minor allele rs2285714 had significantly higher odds of the presence of anastomoses and loops and active neovascular membrane. Furthermore, minor allele carriers had decreased levels of complement factor I level in aqueous humor but not in the plasma, which may be due to the influence of rs2285714 on tissue-specific splicing. Our results suggest that the severity of AMD macular lesions is associated with rs2285714 and rs2230199 polymorphisms, which could be explained by their high regulatory potential. Patients with the minor allele of rs2285714 respond worse to antiangiogenic therapy.
format Online
Article
Text
id pubmed-9312436
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93124362022-07-26 Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration Kozhevnikova, Oyuna S. Fursova, Anzhella Zh. Derbeneva, Anna S. Nikulich, Ida F. Tarasov, Mikhail S. Devyatkin, Vasiliy A. Rumyantseva, Yulia V. Telegina, Darya V. Kolosova, Nataliya G. Biomedicines Article Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss in the elderly. The gold standard of nAMD treatment is intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors. Genetic factors may influence the response to anti-VEGF therapy and result in a high degree of response variability. The aim of the study was to evaluate the association of the polymorphisms in genes related to the complement system (rs2285714-CFI, rs10490924-ARMS2, rs2230199-C3, rs800292-CFH, and rs6677604-CFH) with nAMD its clinical features and optical coherent tomography (OCT) biomarkers of treatment response to anti-VEGF therapy. Genotyping by allele-specific PCR was performed in 193 AMD patients and 147 age-matched controls. A prospective study of the dynamics of changes in OCT biomarkers during aflibercept treatment included 110 treatment-naive patients. Allele T rs10490924 was associated with the increased risk of nAMD. For both rs800292 and rs6677604, carriage of the A allele was protective and decreased the nAMD risk. Associations of rs2230199 with central retinal thickness (CRT) and intraretinal cysts were revealed. The height of pigment epithelium detachment and the height of neuroretinal detachment were significantly higher in carriers of the minor allele of rs2285714, both at baseline and during treatment. The reduction of CRT was associated with higher CRT at baseline and the presence of the T allele of rs2285714. By the end of one-year follow-up the patients homozygous for the minor allele rs2285714 had significantly higher odds of the presence of anastomoses and loops and active neovascular membrane. Furthermore, minor allele carriers had decreased levels of complement factor I level in aqueous humor but not in the plasma, which may be due to the influence of rs2285714 on tissue-specific splicing. Our results suggest that the severity of AMD macular lesions is associated with rs2285714 and rs2230199 polymorphisms, which could be explained by their high regulatory potential. Patients with the minor allele of rs2285714 respond worse to antiangiogenic therapy. MDPI 2022-07-10 /pmc/articles/PMC9312436/ /pubmed/35884963 http://dx.doi.org/10.3390/biomedicines10071658 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kozhevnikova, Oyuna S.
Fursova, Anzhella Zh.
Derbeneva, Anna S.
Nikulich, Ida F.
Tarasov, Mikhail S.
Devyatkin, Vasiliy A.
Rumyantseva, Yulia V.
Telegina, Darya V.
Kolosova, Nataliya G.
Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
title Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
title_full Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
title_fullStr Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
title_full_unstemmed Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
title_short Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
title_sort association between polymorphisms in cfh, arms2, cfi, and c3 genes and response to anti-vegf treatment in neovascular age-related macular degeneration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312436/
https://www.ncbi.nlm.nih.gov/pubmed/35884963
http://dx.doi.org/10.3390/biomedicines10071658
work_keys_str_mv AT kozhevnikovaoyunas associationbetweenpolymorphismsincfharms2cfiandc3genesandresponsetoantivegftreatmentinneovascularagerelatedmaculardegeneration
AT fursovaanzhellazh associationbetweenpolymorphismsincfharms2cfiandc3genesandresponsetoantivegftreatmentinneovascularagerelatedmaculardegeneration
AT derbenevaannas associationbetweenpolymorphismsincfharms2cfiandc3genesandresponsetoantivegftreatmentinneovascularagerelatedmaculardegeneration
AT nikulichidaf associationbetweenpolymorphismsincfharms2cfiandc3genesandresponsetoantivegftreatmentinneovascularagerelatedmaculardegeneration
AT tarasovmikhails associationbetweenpolymorphismsincfharms2cfiandc3genesandresponsetoantivegftreatmentinneovascularagerelatedmaculardegeneration
AT devyatkinvasiliya associationbetweenpolymorphismsincfharms2cfiandc3genesandresponsetoantivegftreatmentinneovascularagerelatedmaculardegeneration
AT rumyantsevayuliav associationbetweenpolymorphismsincfharms2cfiandc3genesandresponsetoantivegftreatmentinneovascularagerelatedmaculardegeneration
AT teleginadaryav associationbetweenpolymorphismsincfharms2cfiandc3genesandresponsetoantivegftreatmentinneovascularagerelatedmaculardegeneration
AT kolosovanataliyag associationbetweenpolymorphismsincfharms2cfiandc3genesandresponsetoantivegftreatmentinneovascularagerelatedmaculardegeneration